The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management
Open accessAbstract
Hypertension is highly prevalent in patients with diabetic nephropathy. Diabetic nephropathy is the leading cause of CKD and end-stage kidney disease in the United States. The etiology of hypertension in diabetic nephropathy involves mechanisms with multiple inter-related mediators that result in renal sodium reabsorption and peripheral vasoconstriction. The management of hypertension in these patients is focused on treatments that target these mediators. Clinical trials have established that drugs that inhibit the renin-angiotensin-aldosterone system should be used as first-line agents on the basis of their ability to slow down progression of kidney disease and lower albuminuria. There is further interest into how the combination of drugs that inhibit this pathway at multiple steps will contribute further to the management of hypertension and diabetic nephropathy. This article presents an updated review of the mechanisms involved in hypertension in patients with diabetic nephropathy. It also reviews the past clinical trials using single agents as therapeutics and the more recent trials involving novel drugs or drug combinations used to treat these patients. Retrospective analyses of multiple studies are included to better examine the significance of the currently proposed blood pressure targets for patients with diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873 · cited 1×
“The IRbesartan in MicroAlbuminuria (IRMA) study evaluated 590 patients with hypertension, DM2 and microalbuminuria and demonstrated that progression to macroalbuminuria was significantly reduced by administration of 300 mg irbesartan compared to placebo (67).”
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Rajagopalan, S., Kurz, S., Münzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K., & Harrison, D. G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118623 · Cited by 2,449
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M., Dworkin, L., Elliott, W. J., Epstein, M., Toto, R., Tuttle, K., Douglas, J., Hsueh, W., & Sowers, J. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,411
Self-citationPoor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
Zoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07217-8 · Cited by 1,087
Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,020
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
Parving, H.-H., Smidt, U., Andersen, A., & Svendsen, P. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92462-5 · Cited by 867
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
Mogensen, C. E. (1982) · BMJ · doi:10.1136/bmj.285.6343.685 · Cited by 760
Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes
Lurbe, E., Redon, J., Kesani, A., Pascual, J. M., Tacons, J., Alvarez, V., & Batlle, D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013410 · Cited by 729
Kunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 717
Diabetes mellitus and hypertension.
Epstein, M., & Sowers, J. R. (1992) · Hypertension · doi:10.1161/01.hyp.19.5.403 · Cited by 600
Achan, V., Broadhead, M., Malaki, M., Whitley, G., Leiper, J., MacAllister, R., & Vallance, P. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000081742.92006.59 · Cited by 593
Effect of antihypertensive treatment on kidney function in diabetic nephropathy.
Parving, H. H., Andersen, A. R., Smidt, U. M., Hommel, E., Mathiesen, E. R., & Svendsen, P. A. (1987) · BMJ · doi:10.1136/bmj.294.6585.1443 · Cited by 537
Bakris, G. L., Sarafidis, P. A., Weir, M. R., Dahlöf, B., Pitt, B., Jamerson, K., Velazquez, E. J., Staikos-Byrne, L., Kelly, R. Y., Shi, V., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62100-0 · Cited by 523
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Bakris, G. L. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1555 · Cited by 469
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 1×
“” Aldosterone escape occurs in up to 40% of patients on ACEi or ARBs and may contribute to local renal damage, albuminuria increases, and possibly systemic hypertenson (84,85).”
Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review
Zillich, A. J., Garg, J., Basu, S., Bakris, G. L., & Carter, B. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000231552.10054.aa · Cited by 456
Parving, H.-H., Hommel, E., Mathiesen, E., Skott, P., Edsberg, B., Bahnsen, M., Lauritzen, M., Hougaard, P., & Lauritzen, E. (1988) · BMJ · doi:10.1136/bmj.296.6616.156 · Cited by 448
Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients
Parving, H.-H., Gall, M.-A., Skøtt, P., Jørgensen, H. E., Løkkegaard, H., Jørgensen, F., Nielsen, B., & Larsen, S. (1992) · Kidney International · doi:10.1038/ki.1992.118 · Cited by 440
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure
Ceballos-Picot, I., Witko-Sarsat, V., Merad-Boudia, M., Nguyen, A. T., Thévenin, M., Jaudon, M. C., Zingraff, J., Verger, C., Jingers, P., & Descamps-Latscha, B. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(96)00233-x · Cited by 396
The effect of insulin on renal sodium metabolism: A review with clinical implications
DeFronzo, R. A. (1981) · Diabetologia · doi:10.1007/bf00252649 · Cited by 391
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Self-citationKIELSTEIN, J. T., BÖGER, R. H., BODE-BÖGER, S. M., SCHÄFFER, J., BARBEY, M., KOCH, K. M., & FRÖLICH, J. C. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103594 · Cited by 361
Abbasi, F., Asagmi, T., Cooke, J. P., Lamendola, C., McLaughlin, T., Reaven, G. M., Stuehlinger, M., & Tsao, P. S. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02063-x · Cited by 354
(2004) · Epilepsy in Children, 2E · doi:10.1201/b13560-9 · Cited by 351
Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy
Tikellis, C., Johnston, C. I., Forbes, J. M., Burns, W. C., Burrell, L. M., Risvanis, J., & Cooper, M. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000060689.38912.cb · Cited by 350
Berl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Pohl, M., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090763 · Cited by 322
Li, L., Fink, G. D., Watts, S. W., Northcott, C. A., Galligan, J. J., Pagano, P. J., & Chen, A. F. (2003) · Circulation · doi:10.1161/01.cir.0000051459.74466.46 · Cited by 317
Anderson, S., Jung, F. F., & Ingelfinger, J. R. (1993) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1993.265.4.f477 · Cited by 307
PLASMA ENDOTHELIN LEVELS IN PATIENTS WITH URAEMIA
Koyama, H., Nishzawa, Y., Morii, H., Tabata, T., Inoue, T., & Yamaji, T. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92631-7 · Cited by 286
The Paradox of the Low-Renin State in Diabetic Nephropathy
PRICE, D. A., PORTER, L. E., GORDON, M., FISHER, N. D. L., DE'OLIVEIRA, J. M. F., LAFFEL, L. M. B., PASSAN, D. R., WILLIAMS, G. H., & HOLLENBERG, N. K. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10112382 · Cited by 272
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
de Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C.-E., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070667 · Cited by 271
Angiotensin-Converting Enzyme II in the Heart and the Kidney
Danilczyk, U., & Penninger, J. M. (2006) · Circulation Research · doi:10.1161/01.res.0000205761.22353.5f · Cited by 269
Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L., & Parving, H.-H. (2004) · Diabetologia · doi:10.1007/s00125-004-1542-0 · Cited by 249
Renal disease and hypertension in non–insulin-dependent diabetes mellitus
Ismail, N., Becker, B., Strzelczyk, P., & Ritz, E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00232.x · Cited by 242
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 239
Jacobsen, P., Andersen, S., Rossing, K., Jensen, B. R., & Parving, H.-H. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00940.x · Cited by 226
Rossing, K., Jacobsen, P., Pietraszek, L., & Parving, H.-H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2268 · Cited by 225
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Tarnow, L., Rossing, P., & Parving, H. H. (2006) · Kidney International · doi:10.1038/sj.ki.5001580 · Cited by 215
Hemodialysis-associated hypertension: Pathophysiology and therapy
Hörl, M. P., & Hörl, W. H. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.30542 · Cited by 215
Jacobsen, P., Andersen, S., Jensen, B. R., & Parving, H.-H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000054495.96193.bf · Cited by 209
Oxidative stress and inflammation in hemodialysis patients
Spittle, M. A., Hoenich, N. A., Handelman, G. J., Adhikarla, R., Homel, P., & Levin, N. W. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.29280 · Cited by 205
Diabetic Nephropathy Is Associated with Oxidative Stress and Decreased Renal Nitric Oxide Production
Prabhakar, S., Starnes, J., Shi, S., Lonis, B., & Tran, R. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080895 · Cited by 203
Genetic Factors in Diabetic Nephropathy
Freedman, B. I., Bostrom, M., Daeihagh, P., & Bowden, D. W. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02560607 · Cited by 195
Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension
Vaziri, N. D., Oveisi, F., & Ding, Y. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00947.x · Cited by 190
Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus
de Châtel, R., Weidmann, P., Flammer, J., Ziegler, W. H., Beretta-Piccoli, C., Vetter, W., & Reubi, F. C. (1977) · Kidney International · doi:10.1038/ki.1977.132 · Cited by 182
Tarnow, L., Hovind, P., Teerlink, T., Stehouwer, C. D. A., & Parving, H.-H. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.765 · Cited by 182
Insulin action and insulin resistance in vascular endothelium
Muniyappa, R., & Quon, M. J. (2007) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32819f8ecd · Cited by 173
Role of nitric oxide in diabetic nephropathy
Prabhakar, S. S. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2004.04.005 · Cited by 167
Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy
Schwartz, M. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.10.2547 · Cited by 164
Matsuguma, K., Ueda, S., Yamagishi, S.-I., Matsumoto, Y., Kaneyuki, U., Shibata, R., Fujimura, T., Matsuoka, H., Kimoto, M., Kato, S., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121379 · Cited by 160
Sodium Induces Hypertrophy of Cultured Myocardial Myoblasts and Vascular Smooth Muscle Cells
Gu, J.-W., Anand, V., Shek, E. W., Moore, M. C., Brady, A. L., Kelly, W. C., & Adair, T. H. (1998) · Hypertension · doi:10.1161/01.hyp.31.5.1083 · Cited by 157
Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade
Khosla, N., Kalaitzidis, R., & Bakris, G. L. (2009) · American Journal of Nephrology · doi:10.1159/000237742 · Cited by 155
Persson, F., Rossing, P. R., Reinhard, H., Juhl, T. R., Stehouwer, C. D. A., Schalkwijk, C. G., Danser, A. H. J., Boomsma, F., Frandsen, E. L., & Parving, H. (2009) · Diabetes Care · doi:10.2337/dc09-0168 · Cited by 151
Spallone, V., Gambardella, S., Maiello, M. R., Barini, A., Frontoni, S., & Menzinger, G. (1994) · Diabetes Care · doi:10.2337/diacare.17.6.578 · Cited by 142
Persson, F., Rossing, P. R., Schjoedt, K. J., Juhl, T. R., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C., Boomsma, F., Frandsen, E., & Parving, H.-H. (2008) · Kidney International · doi:10.1038/ki.2008.68 · Cited by 136
Prevalence of hypertension in Type 1 (insulin-dependent) diabetes mellitus
N�rgaard, K., Feldt‐Rasmussen, B., Borch‐Johnsen, K., S�lan, H., & Deckert, T. (1990) · Diabetologia · doi:10.1007/bf00404089 · Cited by 133
Renal findings in patients with short-term type 2 diabetes.
Keller, C. K., Bergis, K., Fliser, D., & Ritz, E. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v7122627 · Cited by 132
Ogawa, S., Mori, T., Nako, K., KATO, T., Takeuchi, K., & Ito, S. (2006) · Hypertension · doi:10.1161/01.hyp.0000203826.15076.4b · Cited by 132
FACCHINI, F., Stoohs, R. A., & Reaven, G. M. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)87747-8 · Cited by 122
Parving, H., Hommel, E. E., Jensen, B. R., & Hansen, H. P. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00790.x · Cited by 104
Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes
Andersen, N. H., Poulsen, P. L., Knudsen, S. T., Poulsen, S. H., Eiskjær, H., Hansen, K. W., Helleberg, K., & Mogensen, C. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.273 · Cited by 99
Tuck, M. L., Corry, D. B., & Trujillo, A. L. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90144-3 · Cited by 94
Koomans, H. A., Roos, J. C., Mees, E. J. D., & Delawi, I. M. (1985) · Hypertension · doi:10.1161/01.hyp.7.5.714 · Cited by 89
Gnudi, L., Viberti, G., Raij, L. R., Rodriguez, V., Burt, D. J., Cortés, P., Hartley, B., Thomas, S., Maestrini, S., & Gruden, G. (2003) · Hypertension · doi:10.1161/01.hyp.0000075949.19968.ef · Cited by 86
Widespread tissue distribution of human chymase.
Urata, H., Strobel, F., & Ganten, D. (1994) · PubMed · Cited by 85
Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients.
Fagerudd, J. A., Tarnow, L., Jacobsen, P. K., Stenman, S., Nielsen, F. S., Pettersson-Fernholm, K. J., Grönhagen‐Riska, C., Parving, H., & Groop, P. (1998) · Diabetes · doi:10.2337/diabetes.47.3.439 · Cited by 79
Tissue Gene Expression of Renin-Angiotensin System in Human Type 2 Diabetic Nephropathy
Konoshita, T., Wakahara, S., Mizuno, S., Motomura, M., Aoyama, C., Makino, Y., Kawai, Y., Kato, N., Koni, I., Miyamori, I., et al. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1873 · Cited by 73
Nielsen, F. S., Hansen, H. P., Jacobsen, P. K., Rossing, P. R., Smidt, U., Christensen, N. J., Pévet, P., VIVIEN‐ROELS, B., & Parving, H. ‐. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00127.x · Cited by 71
PRICE, D., DEOLIVEIRA, J., Fisher, N. D. L., WILLIAMS, G., & Hollenberg, N. K. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)86960-5 · Cited by 61
Kaplan, N. M., Palmer, B. F., & Palmer, B. F. (2001) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200106000-00005 · Cited by 59
Renal ACE immunohistochemical localization in NIDDM patients with nephropathy
Mizuiri, S., Yoshikawa, H., Tanegashima, M., Miyagi, M., Kobayashi, M., Sakai, K., Hayashi, I., Aikawa, A., Ohara, T., & Hasegawa, A. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9469501 · Cited by 57
Sodium Sensitivity Related to Albuminuria Appearing Before Hypertension in Type 2 Diabetic Patients
Imanishi, M., Yoshioka, K., Okumura, M., Konishi, Y., Okada, N., Morikawa, T., Satō, T., Tanaka, S., & Fujii, S. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.111 · Cited by 56
Dhaun, N., Ferro, C. J., Davenport, A. P., Haynes, W. G., Goddard, J., & Webb, D. J. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm364 · Cited by 52
Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy
Joss, N., Ferguson, C., Brown, C., Deighan, C. J., Paterson, K., & Boulton‐Jones, J. M. (2004) · QJM · doi:10.1093/qjmed/hch039 · Cited by 37
Liniger, C., Favre, L., & Assal, J. ‐. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01625.x · Cited by 36
Effective Antihypertensive Strategies for High-Risk Patients with Diabetic Nephropathy
Buren, P. N. V., ADAMS-HUET, B. A., & Toto, R. D. (2010) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181ff46a5 · Cited by 12
Self-citationPREVENTION OF MICROALBUMINURIA IN TYPE 2 DIABETES (ROADMAP TRIAL): 6A.02
Haller, H. G., Ito, S., Izzo, J. J., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L., et al. (2010) · Journal of Hypertension · doi:10.1097/01.hjh.0000378896.82588.5c · Cited by 9
Role of Glomerular Filtration Rate in Controlling Blood Pressure Early in Diabetes
Brands, M. W., & Labazi, H. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.090647 · Cited by 9
Cited by
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions
Sanajou, D., Ghorbani Haghjo, A., Argani, H., & Aslani, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.001 · Cited by 313
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
Animal models for induction of diabetes and its complications
Qamar, F., Sultana, S., & Sharma, M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01277-3 · Cited by 24
Metadata
- Authors
- Van Buren, P. N., & Toto, R.
- Venue
- Advances in Chronic Kidney Disease
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 18
- Issue
- 1
- Pages
- 28-41
- ISSN
- 1548-5595 (ISSN-L)
- OpenAlex
- W2156364071
- Cited by
- 256
- References
- 95
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.